Tiziana enrols first patient in Phase IIa trial of milciclib to treat HCC
UK-based biotechnology firm Tiziana Life Sciences has started patient enrolment in a Phase IIa clinical trial of milciclib for the treatment of hepatocellular carcinoma (HCC) patients.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Cancer & Oncology | Carcinoma | Clinical Trials | Hepatocellular Carcinoma | Liver Cancer | Pharmaceuticals